Guangdong Marubi Biotechnology Co., Ltd. (SHA:603983)
China · Delayed Price · Currency is CNY 30.86
+0.46 (1.51%)
Sep 30, 2026, 3:00 PM CST
SHA:603983 Ratios and Metrics
Market cap in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Total Valuation
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 29, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 12,375 | 13,293 | 12,936 | 10,133 | 13,545 | 12,806 | |
Market Cap Growth | -22.07% | 2.76% | 27.66% | -25.19% | 5.77% | -38.83% |
Enterprise Value | 10,974 | 11,879 | 11,157 | 8,867 | 12,281 | 10,808 |
Last Close Price | 30.86 | 32.86 | 31.40 | 23.98 | 31.74 | 29.76 |
Price Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 29, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
PE Ratio | 53.43 | 53.77 | 37.87 | 39.06 | 77.76 | 51.65 |
Forward PE | 38.81 | 27.36 | 29.69 | 30.89 | 45.45 | 34.27 |
PS Ratio | 3.69 | 3.84 | 4.36 | 4.55 | 7.82 | 7.17 |
PB Ratio | 3.60 | 3.92 | 3.75 | 2.96 | 4.16 | 4.06 |
P/TBV Ratio | 4.13 | 4.53 | 4.83 | 3.86 | 5.55 | 5.52 |
P/FCF Ratio | - | 193.70 | - | 120.67 | - | - |
P/OCF Ratio | 71.35 | 48.54 | 43.05 | 29.98 | 279.64 | - |
PEG Ratio | - | 0.91 | 0.86 | 1.93 | 4.07 | 3.81 |
EV Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 29, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
EV/Sales Ratio | 3.27 | 3.43 | 3.76 | 3.98 | 7.09 | 6.05 |
EV/EBITDA Ratio | 52.85 | 40.94 | 30.67 | 46.14 | 79.69 | 46.62 |
EV/EBIT Ratio | 81.80 | 51.34 | 32.89 | 50.58 | 89.26 | 49.96 |
EV/FCF Ratio | - | 173.09 | - | 105.59 | - | - |
Financial Efficiency
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 29, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Debt / Equity Ratio | 0.12 | 0.12 | 0.23 | 0.08 | 0.08 | 0.01 |
Debt / EBITDA Ratio | 1.97 | 1.37 | 2.16 | 1.28 | 1.65 | 0.08 |
Debt / FCF Ratio | - | 5.80 | - | 3.04 | - | - |
Net Debt / Equity Ratio | -0.42 | -0.41 | -0.49 | -0.55 | -0.48 | -0.52 |
Net Debt / EBITDA Ratio | -7.05 | -4.81 | -4.61 | -9.72 | -10.21 | -7.07 |
Net Debt / FCF Ratio | 92.28 | -20.34 | 105.88 | -22.25 | 25.19 | 13.16 |
Asset Turnover | 0.72 | 0.72 | 0.62 | 0.52 | 0.44 | 0.47 |
Inventory Turnover | 4.04 | 3.94 | 4.05 | 4.11 | 3.84 | 4.73 |
Quick Ratio | 1.64 | 1.55 | 1.59 | 2.15 | 2.88 | 3.00 |
Current Ratio | 1.94 | 1.87 | 1.85 | 2.50 | 3.35 | 3.43 |
Return on Equity (ROE) | 6.67% | 7.21% | 9.97% | 8.32% | 5.22% | 7.83% |
Return on Assets (ROA) | 1.78% | 2.99% | 4.46% | 2.56% | 2.19% | 3.58% |
Return on Invested Capital (ROIC) | 5.82% | 10.25% | 18.39% | 9.51% | 6.98% | 15.78% |
Return on Capital Employed (ROCE) | 3.90% | 6.80% | 9.80% | 5.10% | 4.00% | 6.80% |
Yields
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 29, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Earnings Yield | 1.84% | 1.86% | 2.64% | 2.56% | 1.29% | 1.94% |
FCF Yield | -0.13% | 0.52% | -0.12% | 0.83% | -0.46% | -0.97% |
Dividend Yield | 1.62% | 1.52% | 2.39% | 2.17% | 0.79% | 0.64% |
Payout Ratio | 43.96% | 121.70% | 91.66% | 40.90% | 44.08% | 57.24% |
Buyback Yield / Dilution | 2.18% | 0.78% | -0.70% | 1.47% | -1.30% | 0.12% |
Total Shareholder Return | 3.80% | 2.30% | 1.68% | 3.64% | -0.51% | 0.76% |